title: [TRAIL impacts in growth and apoptosis of human ovarian carcinoma cell line SKOV3].
abstract: OBJECTIVE
  To investigate the effect of TRAIL on growth and apoptosis of ovarian carcinoma cell line SKOV3.
  
  
  METHODS
  The effects of TRAIL alone and/or associating with DDP to treat on SKOV3 cells growth inhibition were measured by MTT assay, and the changes of DR4 and DR5 mRNA were detected by RT-PCR technique. The cell cycle and apoptosis index were analyzed by technique of Flow Cytometry (FCM).
  
  
  RESULTS
  The soluble TRAIL protein had the inhibiting effect on the growth SKOV3 cells. The DDP increased the ability of TRAIL to SKOV3 cell growth inhibition. The apoptotic indexes (AI) of SKOV3 cells detected by FCM were 5.9%, 13.4% and 39.5% for control group, TRAIL group and TRAIL plus DDP group, respectively. The DDP increased the DR5 expressing in SKOV3 cells by 1.95 folds than control group and by 1.54 times for the DR4 expressing than the control group (P < 0.05).
  
  
  CONCLUSIONS
  The soluble TRAIL has the effect on inhibiting the growth of SKOV3 cells. The combination use of TRAIL and DDP increases significantly the growth-inhibiting ratio to SKOV3 cells. The AI of SKOV3 cell is raised after TRAIL intervening in. The DDP can increase the expressions of DR4 and DR5 in SKOV3 cells.
authors.affiliation: Department of Gynecology and Cbstetrics, West China Second Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Chun-mei
authors.initials: CM
authors.lastname: Li
authors.forename: Zhi-lan
authors.initials: ZL
authors.lastname: Peng
authors.forename: Ru-tie
authors.initials: RT
authors.lastname: Yin
authors.forename: Min
authors.initials: M
authors.lastname: Hu
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D018284:Cystadenocarcinoma, Serous / Q000473:pathology; D004357:Drug Synergism; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000473:pathology*; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000096:biosynthesis* / Q000235:genetics; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D053221:TNF-Related Apoptosis-Inducing Ligand; D002945:Cisplatin